Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations
暂无分享,去创建一个
[1] D. Back,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.
[2] J. Porter,et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia , 1998, AIDS.
[3] M. Narita,et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. , 1998, American journal of respiratory and critical care medicine.
[4] C. Whitney,et al. Risk factors for rifampin mono-resistant tuberculosis. , 1998, American journal of respiratory and critical care medicine.
[5] W. El-Sadr,et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] M. Feinberg,et al. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .
[7] R. Chaisson,et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection , 1998, The Lancet.
[8] L. Haramati,et al. Effect of HIV status on chest radiographic and CT findings in patients with tuberculosis. , 1997, Clinical radiology.
[9] A. Li,et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.
[10] M. Vjecha,et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, The New England journal of medicine.
[11] A. Rachlis,et al. Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection , 1997, Annals of Internal Medicine.
[12] J P Matts,et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] W. El-Sadr,et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. , 1997, The New England journal of medicine.
[14] K. Castro,et al. A Nosocomial Outbreak of Multidrug-Resistant Tuberculosis , 1997, Annals of Internal Medicine.
[15] F. Plummer,et al. Isoniazid preventive therapy for tuberculosis in HIV‐1‐infected adults: results of a randomized controlled trial , 1997, AIDS.
[16] R. Ridzon,et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. , 1997, American journal of respiratory and critical care medicine.
[17] R. Klein,et al. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. Hom,et al. Site of disease and opportunistic infection predict survival in HIV‐associated tuberculosis , 1997, AIDS.
[19] Y. Cao,et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. , 1997, American journal of respiratory and critical care medicine.
[20] P. Kvale,et al. Incidence of Tuberculosis in the United States among HIV-Infected Persons , 1997, Annals of Internal Medicine.
[21] M. Felten,et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. , 1996, American journal of respiratory and critical care medicine.
[22] W. El-Sadr,et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. , 1996, American journal of respiratory and critical care medicine.
[23] J. Mcgowan,et al. Clinical predictors of tuberculosis as a guide for a respiratory isolation policy. , 1996, American journal of respiratory and critical care medicine.
[24] D. Gottlieb,et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. , 1996, American journal of respiratory and critical care medicine.
[25] J. T. Crawford,et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. , 1996, JAMA.
[26] T. Frieden,et al. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. , 1996, JAMA.
[27] R. Chaisson,et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. , 1996, American journal of respiratory and critical care medicine.
[28] D. Weissman,et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.
[29] R. Chaisson,et al. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. , 1996, The New England journal of medicine.
[30] M. Vjecha,et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. , 1996, American journal of respiratory and critical care medicine.
[31] D. Vlahov,et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. , 1996, Archives of internal medicine.
[32] R. Shafer,et al. Predictors of survival in HIV‐infected tuberculosis patients , 1996, AIDS.
[33] T. Perneger,et al. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years , 1995, BMJ.
[34] K. D. de Cock,et al. Autopsy‐proven causes of death in HIV‐infected patients treated for tuberculosis in Abidjan, Côte d'lvoire , 1995, AIDS.
[35] K. Gallicano,et al. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. , 1995, Clinical Infectious Diseases.
[36] K. D. de Cock,et al. Two‐year follow‐up of persons with HIV‐1− and HIV‐2‐associated pulmonary tuberculosis treated with short‐course chemotherapy in West Africa , 1995, AIDS.
[37] R. Chaisson,et al. Eleven years of community-based directly observed therapy for tuberculosis. , 1995, JAMA.
[38] A. Bloch,et al. Essential components of a tuberculosis prevention and control program; Screening for tuberculosis and tuberculosis infection in high risk populations : recommendations of the Advisory Council for the Elimination of Tuberculosis , 1995 .
[39] R. Wallace,,et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] T. Hooton,et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. , 1995, American journal of respiratory and critical care medicine.
[41] K. Holmes,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] G. Rao,et al. Paradoxical progression of tuberculous lesions during chemotherapy of central nervous system tuberculosis. Report of four cases. , 1995, Journal of neurosurgery.
[43] P. Davidson. Managing tuberculosis during pregnancy , 1995, The Lancet.
[44] R. O'brien,et al. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. , 1995, AIDS.
[45] Lewis D. Griffin,et al. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. , 1995, Archives of internal medicine.
[46] M. Dietrich,et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[47] W. Rom,et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. , 1995, The Journal of clinical investigation.
[48] P. Piot,et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. , 1995, New England Journal of Medicine.
[49] K. D. de Cock,et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire , 1995, The Lancet.
[50] P. Barnes,et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. , 1994, American journal of respiratory and critical care medicine.
[51] M. Vjecha,et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans , 1994, The Lancet.
[52] S. Natal,et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[53] R. Chaisson,et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV‐infected patients , 1994, AIDS.
[54] M. Lederman,et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.
[55] G. Schoolnik,et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. , 1994, The New England journal of medicine.
[56] D Alland,et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. , 1994, The New England journal of medicine.
[57] D. Cohn. Treatment and prevention of tuberculosis in HIV-infected persons. , 1994, Infectious Disease Clinics of North America.
[58] S. Weis,et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. , 1994, The New England journal of medicine.
[59] D. Mitchison,et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. , 1993, The Journal of antimicrobial chemotherapy.
[60] J. Pape,et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.
[61] M. Iseman,et al. Malabsorption of antituberculosis medications by a patient with AIDS. , 1992, The New England journal of medicine.
[62] T. Singh,et al. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition. , 1992, Archives of internal medicine.
[63] K. D. de Cock,et al. Tuberculosis and HIV infection in sub-Saharan Africa. , 1992, JAMA.
[64] J. T. Crawford,et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. , 1992, JAMA.
[65] J. T. Crawford,et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.
[66] G. Schoolnik,et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.
[67] R. Shafer,et al. Extrapulmonary Tuberculosis in Patients with Human Immunodeficiency Virus Infection , 1991, Medicine.
[68] P. Piot,et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. , 1991, The American review of respiratory disease.
[69] R. Chaisson,et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. , 1991, The New England journal of medicine.
[70] J. Justement,et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms , 1990, The Journal of experimental medicine.
[71] D. Snider,et al. Epidemiology of tuberculosis in the United States. , 1989, Epidemiologic reviews.
[72] A. Fauci,et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[73] G. Nabel,et al. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[74] S. Vermund,et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.
[75] J. Justement,et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.
[76] R. Chaisson,et al. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. , 1987, The American review of respiratory disease.
[77] A. Fauci,et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. , 1987, JAMA.
[78] G. Scott,et al. Acute respiratory distress related to chemotherapy of advanced pulmonary tuberculosis: a study of two cases and review of the literature. , 1986, The Quarterly journal of medicine.
[79] J. Ellner. Suppressor adherent cells in human tuberculosis. , 1978, Journal of immunology.
[80] Mark A. Miller,et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. , 1998, The Journal of infectious diseases.
[81] P. Hopewell,et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. , 1998, American journal of respiratory and critical care medicine.
[82] J. Musser,et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. , 1996, American journal of respiratory and critical care medicine.
[83] A. Boobis,et al. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. , 1986, British journal of clinical pharmacology.